SCHEMBL29968094

SCHEMBL29968094

Cc1n[nH]c2ncc(CN3CCc4ccc(C(=O)Nc5cc(OCCN6CCCC6)cc(C(F)(F)F)c5)cc43)cc12

nearest known ligand 0.45

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ BRAF P15056 6/20 0.45
▸ DDR2 Q16832 9/20 0.42
▸ DDR1 Q08345 7/20 0.42
▸ ABL1 P00519 5/20 0.41
▸ BCR P11274 2/20 0.41
▸ KIT P10721 1/20 0.40
▸ KDR P35968 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ NTRK3 Q16288 1/20 0.40
▸ NTRK2 Q16620 1/20 0.40
▸ JAK2 O60674 1/20 0.39
▸ SRC P12931 1/20 0.39
▸ HTR2A P28223 1/20 0.39
▸ HTR2C P28335 1/20 0.39
▸ PARP1 P09874 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27081726 1.00 BRAF (0.45) BRAFDDR2DDR1ABL1BCR
SCHEMBL29967389 0.89 DDR2 (0.51) BRAFDDR2DDR1ABL1BCR
SCHEMBL27081794 0.89 DDR2 (0.51) BRAFDDR2DDR1ABL1BCR
SCHEMBL29968090 0.87 DDR2 (0.56) DDR2DDR1ABL1BCRKIT
SCHEMBL27081787 0.87 DDR2 (0.56) DDR2DDR1ABL1BCRKIT
SCHEMBL27082011 0.85 DDR2 (0.45) DDR2DDR1ABL1BCRKIT
SCHEMBL29967998 0.85 DDR2 (0.45) DDR2DDR1ABL1BCRKIT
SCHEMBL29968231 0.84 WNT1 (0.42) BRAFDDR2DDR1ABL1BCR
SCHEMBL27081627 0.84 WNT1 (0.42) BRAFDDR2DDR1ABL1BCR
SCHEMBL29967917 0.82 DDR1 (0.56) DDR2DDR1ABL1BCRKIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP claimed
EP-4313972-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2024-02-07 — — EP claimed
CN-117062812-A Indoline derivatives as DDR inhibitors 奇斯药制品公司 2023-11-14 — — CN claimed
WO-2022200577-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2022-09-29 — — WO claimed
EP-4313972-B1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARM SPA (IT) 2025-01-29 — — EP disclosed
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-07-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240217967-A1 INDOLINE DERIVATIVES AS DDRS INHIBITORS DDR1, DDR2, DDRGK1 BRAF 799/4885DDR2 2/4885DDR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback